Printer Friendly

CELGENE AND BETZ LABORATORIES FORM STRATEGIC ALLIANCE TO COMMERCIALIZE CELGENE'S BIOTREATMENT TECHNOLOGY

 WARREN, N.J. and TREVOSE, Pa., Jan. 12 /PRNewswire/ -- Celgene Corporation (NASDAQ: CELG) and Betz Laboratories (NYSE: BTL) today announced the formation of a strategic alliance to commercialize Celgene's technology for the treatment of toxic industrial waste effluents.
 Betz will commercialize Celgene's biological treatment systems for reducing levels of specific pollutants in individual process waste streams. Only naturally occurring microorganisms are used in the systems. The agreement provides for exclusive marketing by Betz domestically. Joint efforts will be directed in 1993 toward technical training and market development with more extensive sales efforts to follow in 1994.
 Celgene first demonstrated its proprietary biological treatment systems for the reduction of methylene chloride emissions at a major plastics resin facility in 1991. In November 1992, the company announced the introduction of a new biotreatment system to treat effluents containing toluene, phenol and other aromatic compounds. This second system is currently being demonstrated at a large U.S. chemical plant. Other systems are expected to be announced in the next year.
 "We are pleased to have the support of such a highly regarded organization in the water treatment industry," said John L. Ufheil, chairman, president and chief executive officer of Celgene. "Together we will be able to assist companies in reducing their toxic emissions in an effective and competitively cost efficient manner."
 Betz Laboratories is a leader in industrial water treatment. Its strong field sales force will enable Celgene's in-line pollution prevention systems to be more rapidly introduced into key industries. In turn, the agreement will allow Betz to offer additional value-added environmental management services to its customers.
 "We are excited by the prospects of being able to offer systems which will help reduce some of our nation's most prevalent wastes before they enter the environment," said William R. Cook, president and chief operating officer of Betz Laboratories. "We consider Celgene the leader in this type of biotreatment technology."
 Under the agreement, Betz will have exclusive responsibility for sales and marketing, installation and service, while Celgene will be responsible for continuing technology, development and support.
 Betz Laboratories is engaged in the engineered chemical treatment of water, wastewater, and process systems operating in a variety of industrial and commercial applications. The company produces and markets a wide range of specialty chemical products, and the technical and laboratory services necessary to utilize Betz products effectively. Betz has 14 production plants in the U.S. and seven in foreign countries and employs approximately 4,000 persons. Betz had sales in 1991 of $665.6 million.
 Celgene Corporation, based in Warren, N.J. is a chemical biotechnology company engaged in the development of proprietary biotreatment systems to degrade hazardous wastes and the development and manufacture of high purity chiral chemicals.
 -0- 1/12/93
 /CONTACT: Mr. John L. Ufheil of Celgene Corporation, 908-271-4119; or Mr. R. D. Voncanon of Betz Laboratories, Inc., 215-355-3300; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Celgene/
 (BTL CELG)


CO: Celgene Corporation; Betz Laboratories ST: New Jersey, Pennsylvania IN: MTC SU: WB-LR -- NY072 -- 4012 01/12/93 12:19 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:511
Previous Article:SIX WASHINGTON PROPERTIES ARE 'OUTSTANDING;' 1993 MOBIL TRAVEL GUIDE FOUR-STAR AWARDS ANNOUNCED
Next Article:$50 MILLION IN SUNKEN TREASURE TO BE AUCTIONED IN ATLANTIC CITY
Topics:


Related Articles
CELGENE APPOINTS JOHNSON & JOHNSON EXECUTIVE AS PRESIDENT AND COO
CELGENE GAINS EXCLUSIVE RIGHTS TO THALIDOMIDE UNDER ROCKEFELLER PATENT
CELGENE ELECTS NEW BOARD MEMBER
R.G. WRIGHT TO RETIRE FROM POSTS AS CHAIRMAN AND CHIEF EXECUTIVE OF CELGENE CORPORATION
CELGENE SIGNS AGREEMENT FOR MAJOR EXPANSION OF THALIDOMIDE SUPPLY
ELITE LABORATORIES, INC. ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH CELGENE CORPORATION
Pharmacopeia achieves research milestone in Celgene collaboration.
Celgene Licenses Rights To EntreMed For Tubulin Inhibitor Program.
Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters